Ambroxol-based Vaporizer 'Ianping'
Expected to Grow 3 Times Compared to Last Year
[Asia Economy Reporter Kim Daehyun] Beijing Hanmi Pharmaceutical, the local subsidiary of Hanmi Pharmaceutical Group in China, announced that it expects to surpass 320 billion KRW in annual sales this year by leveraging its new product, the vaporized cough and sputum medicine 'Ianping,' along with its existing main products.
On the 20th, Beijing Hanmi Pharmaceutical stated that 'Ianping,' now in its second year since launch, is expected to be the key driver in achieving 320 billion KRW in sales. Beijing Hanmi Pharmaceutical anticipates that Ianping will achieve sales exceeding 30 billion KRW this year, approximately three times higher than last year.
Ianping is a product that converted the cough and sputum treatment ingredient 'Ambroxol' from an injection to a vaporizer form for the first time in China. Beijing Hanmi Pharmaceutical quickly understood the regulatory environment in the Chinese market and uniquely conducted Phase 3 clinical trials locally to launch the product in vaporizer form.
Previously, during the COVID-19 pandemic, Beijing Hanmi Pharmaceutical demonstrated the effectiveness of Ianping in reducing acute respiratory symptoms and hypersensitive immune response risks through various additional virus-related clinical trials. The company plans to complete a multi-center Phase 4 clinical trial involving over 3,800 cases, initiated last year, within this year, and expand the prescription market further through more than 800 respiratory clinical and academic activities and securing over 1,000 new hospitals.
Beijing Hanmi Pharmaceutical achieved sales of approximately 280 billion KRW last year. It currently sells 19 products in China, including 'Itanjing,' which generates annual sales in the 100 billion KRW range, 'Mamiai' (children's digestive medicine) with sales in the 60 billion KRW range, and 'Litong' (constipation medicine).
Lim Haeryong, General Manager of Beijing Hanmi Pharmaceutical, said, "It is rare to find a pharmaceutical company that has nurtured various self-developed products into blockbusters like Beijing Hanmi Pharmaceutical among pharmaceutical companies entering the Chinese market." He added, "This year as well, we will contribute to Hanmi Pharmaceutical's global journey toward becoming a pharmaceutical powerhouse through Beijing Hanmi Pharmaceutical's sustainable growth and strong performance."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
